Download Files:
Products Details
Product Description
– SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction[1][2].
Web ID
– HY-125182
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C27H30N4O2S
References
– [1]Quentin Nevers, et al. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00126-18.|[2]Abdelhakim Ahmed-Belkacem, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016 Sep 22;7:12777.
CAS Number
– 2649904-85-6
Molecular Weight
– 474.62
SMILES
– O=C(NC(C1=CC=CC=C1)C(N2C(C3=CC=CC=C3SC)CCC2)=O)NCC4=CC=C(N)C=C4
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– HCV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
